Bone Marrow Transplant Rejection – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Bone Marrow Transplant Rejection – Drugs In Development, 2023’, provides an overview of the Bone Marrow Transplant Rejection pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Bone Marrow Transplant Rejection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bone Marrow Transplant Rejection and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Bone Marrow Transplant Rejection
- The report reviews pipeline therapeutics for Bone Marrow Transplant Rejection by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Bone Marrow Transplant Rejection therapeutics and enlists all their major and minor projects
- The report assesses Bone Marrow Transplant Rejection therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Bone Marrow Transplant Rejection
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Bone Marrow Transplant Rejection
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Bone Marrow Transplant Rejection pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
9 Meters Biopharma IncAbbisko Therapeutics Co Ltd
AbbVie Inc
AbolerIS Pharma
Accro Bioscience Suzhou Co Ltd
Actitrexx GmbH
Adienne Pharma & Biotech SA
Aegle Therapeutics Corp
AffyXell Therapeutics Co Ltd
Alphamab Oncology
AltruBio Inc
AnaMar AB
AnaptysBio Inc
ARScience Biotherapeutics Inc
ASC Therapeutics Inc
AstraZeneca Plc
Athos Therapeutics Inc
Avalon GloboCare Corp
Azura Ophthalmics Pty Ltd
Baudax Bio Inc
Bellicum Pharmaceuticals Inc
Biocon Ltd
Biogen Inc
BioIncept LLC
Biotech Pharmaceutical Co Ltd
Biotest AG
BK Pharmaceuticals Ltd
BlueRock Therapeutics LLC
BlueSphere Bio Inc
Boryung ViGenCell Inc
Boston Immune Technologies and Therapeutics Inc
Bristol-Myers Squibb Co
Capricor Therapeutics Inc
Cell Source Inc
Cellective BioTherapy Inc
Cellenkos Inc
Cellestia Biotech AG
Celloram Inc
Celltrion Inc
Cellvation Inc
CheckPoint Immunology Inc
Cincinnati Children's Hospital Medical Center
City of Hope
Compugen Ltd
Corvus Pharmaceuticals Inc
Createrna Science and Technology Co Ltd
Crestone Inc
CSL Ltd
CTI BioPharma Corp
Cue Biopharma Inc
Cytopeutics Pte Ltd
Daewoong Pharmaceutical Co Ltd
Dmitry Rogachev National Research Center of Pediatric Hematology
Oncology and Immunology
Dualogics Corp
Dualyx NV
Dystrogen Therapeutics SA
Educell doo
Eli Lilly and Co
Emory University
enGene Holdings Inc
Equillium Inc
EV Therapeutics Inc
Evive Biotech
ExCellThera Inc
F. Hoffmann-La Roche Ltd
Faron Pharmaceuticals Oy
Forte Biosciences Inc
Fraunhofer Institute for Cell Therapy and Immunology
French National Institute of Health and Medical Research
Fujifilm Holdings Corp
Genentech USA Inc
General Nanotherapeutics LLC
GigaGen Inc
Glia LLC
Good T Cells Inc
Gracell Biotechnologies Inc
GSK plc
Guangdong ProCapZoom Biosciences Co Ltd
H. Lee Moffitt Cancer Center & Research Institute Inc
Hangzhou East China Pharmaceutical Group Co Ltd
HiFiBiO Therapeutics Inc
Humanigen Inc
iCELL Biotechnology Co Ltd
Immune Modulation Inc
ImmuneMed Inc
ImmunoBiome Inc
Imstem Biotechnology Inc
Incyte Corp
Indiana University
Inhibrx Inc
iNtRON Biotechnology Inc
Iovance Biotherapeutics Inc
Ironwood Pharmaceuticals Inc
ITB-Med AB
Jiangsu Hengrui Medicine Co Ltd
JN Biosciences LLC
Kadmon Holdings Inc
Kamada Pharmaceuticals
Kiji Therapeutics
Kymab Ltd
Lipella Pharmaceuticals Inc
Lysatpharma GmbH
MaaT Pharma
Machavert Pharmaceuticals LLC
Medexus Pharmaceuticals Inc
Mediolanum farmaceutici SpA
Medsenic SAS
Merck & Co Inc
Mereo Biopharma Group Plc
Mesoblast Ltd
Millennium Pharmaceuticals Inc
MiNK Therapeutics Inc
MitoImmune Therapeutics Inc
Moderna Inc
Monash University
NapaJen Pharma Inc
Neoleukin Therapeutics Inc
Neovii Pharmaceuticals AG
NeuImmune Inc
Novartis AG
NXI Therapeutics AG
Orca Biosystems Inc
Oregon State University
Ossium Health Inc
Panorama Research Institute
Parenchyma Biotech
PB Immune Therapeutics Co Ltd
Pfizer Inc
Platinum Biotech (Beijing) Co Ltd
Plexxikon Inc
Pluri Inc
Precision Biosciences Inc
ProGen Co Ltd
ReAlta Life Sciences Inc
Rebus Holdings Inc
Redx Pharma Plc
REGiMMUNE Corp
RHEACELL GmbH & Co KG
Rheos Medicines Inc
Romeck Pharma LLC
San Raffaele Scientific Institute
Sanofi
SCM lifescience Co Ltd
Seagen Inc
Seres Therapeutics Inc
Shanghai Fosun Pharmaceutical (Group) Co Ltd
Shenzhen Chipscreen Biosciences Co Ltd
Sidney Kimmel Comprehensive Cancer Center
Sino Biopharmaceutical Ltd
STERO Biotechs Ltd
StingInn LLC
SUNY Upstate Medical University
Suzhou Connect Biopharmaceuticals Ltd
Suzhou Regend Therapeutics Co Ltd
Suzhou Zelgen Biopharmaceutical Co Ltd
Syndax Pharmaceuticals Inc
Takeda Pharmaceutical Co Ltd
Tcell Tolerance GmbH
TCF GmbH
Theriva Biologics Inc
Tianjin Angsai Cell Genetic Engineering Co Ltd
Tianjin Madison Regenerative Medicine Co Ltd
Trailhead Biosystems Inc
TreeFrog Therapeutics SAS
Triursus Therapeutics Inc
United BioPharma Inc
University of Patras
University of Southern California
Vault Pharma Inc
Vectans Pharma SAS
Veloxis Pharmaceuticals Inc
Viracta Therapeutics Inc
VITRAC Therapeutics LLC
Wake Forest University
Washington University in St Louis
Wistar Institute
Xbiome Co Ltd
Xenothera SAS
Xlock Biosciences LLC
Zephyrm Biotechnologies Co Ltd
Zr Pharma & Gmbh